Literature DB >> 24158828

Single-copy quantification of HIV-1 in clinical samples.

Ann Wiegand1, Frank Maldarelli.   

Abstract

HIV replication in humans proceeds with substantial viral RNA levels in plasma. Antiretroviral therapy results in suppression but not eradication of HIV infection. Continuous therapy is essential for durable clinical responses. Discontinuing antiretroviral therapy results in prompt rebound in viremia. The source of HIV during suppressive therapy and mechanisms of persistence remain uncertain. Sensitive assays for HIV have been useful in quantifying viremia in response to antiretroviral therapy and in experimental studies of drug intensification, drug simplification, and potential anatomic sanctuary site investigations. As clinical eradication strategies move forward, robust, sensitive quantitative assays for HIV at low levels represent essential laboratory support modalities. Here we describe in detail an assay for HIV-1 RNA with single-copy sensitivity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24158828      PMCID: PMC7646261          DOI: 10.1007/978-1-62703-670-2_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  33 in total

1.  Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays.

Authors:  Priscilla Swanson; Vera Holzmayer; Shihai Huang; Phillip Hay; Ade Adebiyi; Philip Rice; Klara Abravaya; Sven Thamm; Sushil G Devare; John Hackett
Journal:  J Virol Methods       Date:  2006-07-28       Impact factor: 2.014

Review 2.  New molecular approaches in the diagnosis of acute diarrhea: advantages for clinicians and researchers.

Authors:  Alfredo Guarino; Antonietta Giannattasio
Journal:  Curr Opin Gastroenterol       Date:  2011-01       Impact factor: 3.287

3.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

Review 4.  Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.

Authors:  Frank Maldarelli
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

5.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

Authors:  D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

6.  Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.

Authors:  Viktor Dahl; Evelyn Lee; Julia Peterson; Serena S Spudich; Idris Leppla; Elizabeth Sinclair; Dietmar Fuchs; Sarah Palmer; Richard W Price
Journal:  J Infect Dis       Date:  2011-10-21       Impact factor: 5.226

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

Authors:  Philip M Grant; Sarah Palmer; Eran Bendavid; Annie Talbot; Debbie C Slamowitz; Pat Cain; Stacy S Kobayashi; Maya Balamane; Andrew R Zolopa
Journal:  J Clin Virol       Date:  2009-10-12       Impact factor: 3.168

9.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  1 in total

1.  Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.

Authors:  Erin G Reid; David Looney; Frank Maldarelli; Ariela Noy; David Henry; David Aboulafia; Juan Carlos Ramos; Joseph Sparano; Richard F Ambinder; Jeannette Lee; Ethel Cesarman; Sara Yahyaei; Ronald Mitsuyasu; William Wachsman
Journal:  Blood Adv       Date:  2018-12-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.